Continuous flow local anesthetic wound infusion for post-operative analgesia following kidney transplantation.
kidney transplantation
local anesthetic pumps
narcotics
opioid use
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
27
01
2024
received:
05
12
2023
accepted:
18
03
2024
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
3
4
2024
Statut:
ppublish
Résumé
Some patients with end stage renal disease are or will become narcotic-dependent. Chronic narcotic use is associated with increased graft loss and mortality following kidney transplantation. We aimed to compare the efficacy of continuous flow local anesthetic wound infusion pumps (CFLAP) with patient controlled analgesia pumps (PCA) in reducing inpatient narcotic consumption in patients undergoing kidney transplantation. In this single-center, retrospective analysis of patients undergoing kidney transplantation, we collected demographic and operative data, peri-operative outcomes, complications, and inpatient oral morphine milligram equivalent (OME) consumption. Four hundred and ninety-eight patients underwent kidney transplantation from 2020 to 2022. 296 (59%) historical control patients received a PCA for postoperative pain control and the next 202 (41%) patients received a CFLAP. Median age [53.5 vs. 56.0 years, p = .08] and BMI [29.5 vs. 28.9 kg/m Compared to PCA, CFLAP provided a 93% reduction in OME consumption with a small increase in the wound-related complication rate. The utility of local anesthetic pumps may also be applicable to patients undergoing any unilateral abdominal or pelvic incision.
Sections du résumé
BACKGROUND
BACKGROUND
Some patients with end stage renal disease are or will become narcotic-dependent. Chronic narcotic use is associated with increased graft loss and mortality following kidney transplantation. We aimed to compare the efficacy of continuous flow local anesthetic wound infusion pumps (CFLAP) with patient controlled analgesia pumps (PCA) in reducing inpatient narcotic consumption in patients undergoing kidney transplantation.
MATERIALS AND METHODS
METHODS
In this single-center, retrospective analysis of patients undergoing kidney transplantation, we collected demographic and operative data, peri-operative outcomes, complications, and inpatient oral morphine milligram equivalent (OME) consumption.
RESULTS
RESULTS
Four hundred and ninety-eight patients underwent kidney transplantation from 2020 to 2022. 296 (59%) historical control patients received a PCA for postoperative pain control and the next 202 (41%) patients received a CFLAP. Median age [53.5 vs. 56.0 years, p = .08] and BMI [29.5 vs. 28.9 kg/m
CONCLUSIONS
CONCLUSIONS
Compared to PCA, CFLAP provided a 93% reduction in OME consumption with a small increase in the wound-related complication rate. The utility of local anesthetic pumps may also be applicable to patients undergoing any unilateral abdominal or pelvic incision.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15305Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
CDC WONDER. Centers for Disease Control and Prevention. 2020. Accessed May 12, 2022.
Mattson CL, Tanz LJ, Quinn K, et al. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013‐2019. MMWR Morb Mortal Wkly Rep. 2021;70:202‐207.
Lafargue MC, Caliskan Y, Lentine KL, et al. Opioids and kidney transplantation. Semin Nephrol. 2021;41:42‐53.
Abbott KC, Fwu CW, Eggers PW, et al. Opioid prescription, morbidity, and mortality in US transplant recipients. Transplantation. 2018;102:994‐1004.
Lentine KL, Lam NN, Naik AS, et al. Prescription opioid use before and after kidney transplant: implications for post‐transplant outcome. Am J Transplant. 2018;18:2987‐2999.
Carcella T, Patel N, Marable J, et al. Long‐term outcomes following a comprehensive quality assurance and process improvement endeavor to minimize opioid use after kidney transplant. JAMA Surg. 2023;158:618‐624.
Muir MA, Szempruch KR, Dupuis R, et al. Utilizing multimodal analgesia to evaluate postoperative analgesic requirements in kidney transplant recipients. Clin Transplant. 2021;4:1‐9.
Tawfic QA, Bellingham G. Postoperative pain management in patients with chronic kidney disease. J Anaesthesiol Clin Pharmacol. 2015;31:6‐13.
Mukhtar K, Khattak I. Transversus abdominis plane blocks for renal transplant recipients. British J Anaesthesia. 2010:663‐664.
Abaza R, Kogan P, Martinez O. Narcotic avoidance after robotic radical cystectomy allows routine of only two‐day hospital stay. Urology. 2022;161:65‐70.
Chung D, Lee YJ, Jo MH, et al. The ON‐Q pain management system in elective gynecology oncologic surgery: management of post‐operative surgical site pain compared to intravenous patient controlled analgesia. Obstet Gynecol Sci. 2013;56:93‐101.
Wheatley GH III, Rosenbaum DH, Paul MC, et al. Improved pain management outcomes with continuous infusion of a local anesthetic after thoracotomy. J Thorac Cardiovasc Surg. 2005;130:464‐468.
Scholz A. Mechanisms of (local) anaesthetics on voltage‐gated sodium and other ion channels. Br J Anaesth. 2002;89:52‐61.
Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017;10:2287‐2298.
Uppal NN, Jhaveri M, Hong S, et al. Local anesthetics for the nephrologist. Clin Kidney J. 2022;15:186‐193.
Plakhotnik J, Zhang L, Estrada M, et al. Local anesthetic cardiac toxicity is mediated by cardiomyocyte calcium dynamics. Anesthesiology. 2022;137:687‐703.